In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck KGaA Health Care Head Happy With Old And New Mix

Pipeline Will Augment Established Strong Sellers

Executive Summary

The German firm’s pharma chief Peter Guenter says that while the firm’s lifecycle management of older products is industry-leading, “innovation is the lifeblood of any pharmaceutical company," and he is confident Merck’s promising pipeline will augment its current big earners.

You may also be interested in...



Merck KGaA Ties Up Chord To Advance Cladribine Rare Disease Programs

Merck will develop Chord’s lead drug candidate, an oral version of cladribine, for the treatment of neuromyelitis optica spectrum disorders and generalized myasthenia gravis.

GSK Exits $4.2bn Cancer Drug Deal With Merck KGaA After Multiple Failures

Bintrafusp alfa was once seen as a blockbuster contender by the partners but GSK’s withdrawal narrows further its chances of success.

Rigel Ready To Hit The Ground Running After Early AML Drug Approval

Rezlidhia, which was only recently licensed by Rigal from Novo Nordisk-owned Forma Therapeutics, should challenge the market dominance of Servier's Tibsovo in the IDH-1 inhibitor subset of acute myeloid leukemia patients. 

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

IV125052

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel